Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 11, 2026Neurological SciencesOpen Access

Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDiamante CartaVBViviana Lo BuonoRGRosario Grugno

Discussion

Loading...

Member takes

Overview

Systematic review evaluates CGRP monoclonal antibodies' efficacy and safety in chronic migraine, indicating meaningful benefits.

Key Points

  • This review assesses the efficacy and safety of CGRP-targeted monoclonal antibodies for chronic migraine prevention.
  • Conducted comprehensive literature search across PubMed, Scopus, and Web of Science until July 2025.
  • Included randomized controlled trials and real-world studies involving CGRP-targeted monoclonal antibodies in adults with chronic migraine.
  • Followed PRISMA 2020 guidelines and registered in PROSPERO database (CRD420261284751).
  • CGRP-targeted monoclonal antibodies showed consistent reductions in migraine frequency and ≥ 50% responder rates.
  • Randomized controlled trials demonstrated robust efficacy compared to placebo, while real-world studies confirmed effectiveness in diverse populations.
  • Noted variability in outcome definitions and study designs contributed to heterogeneity across findings.

Cite This Study

Carta et al. (2026) studied this question.

synapsesocial.com/papers/6a2a523480c8f91e7f39e3cbhttps://doi.org/10.1007/s10072-026-09153-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1EFFECTIVENESS AND SAFETY OF ANTI-CGRP MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION IN REAL-WORLD PRACTICE: A SYSTEMATIC REVIEW2026
  2. 2Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence2024 · 2 citations
  3. 3SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials2025 · 4 citations
  4. 4Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysis2026 · 1 citations
  5. 5CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025 · 15 citations